Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of a targeted next-generation sequencing panel for pancreatic ductal adenocarcinomas.

Experimental and molecular pathology - 1 Oct 2024

Racu Marie-Lucie, Schiavo Andrea Alex, Van Campenhout Claude, De Nève Nancy, Masuy Thomas, Maris Calliope, Decaestecker Christine, Remmelink Myriam, Salmon Isabelle, D'Haene Nicky

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is reported to be amongst the cancers with the lowest survival rate at 5 years. In the present study we aimed to validate a targeted next-generation sequencing (tNGS) panel to use in clinical routine, investigating genes important for PDAC diagnostic, prognostic and potential theragnostic aspect. In this NGS panel we also designed target regions to inquire about loss of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to High-Throughput Nucleotide Sequencing

Share to Loss of Heterozygosity

Share to Pancreatic Neoplasms

Share to Prognosis

Share to Smad4 Protein

Source

Identifiers

PMID: 39033589
DOI: 10.1016/j.yexmp.2024.104920

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of a targeted next-generation sequencing panel for pancreatic ductal adenocarcinomas.PMID 39033589Read ↗

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene PanelSemantic proximity Read ↗

Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?Semantic proximity Read ↗

Targeted Sequencing of Pancreatic Ductal Adenocarcinoma TissueSemantic proximity Read ↗

Next-Generation Sequencing in Pancreatic CancerSemantic proximity Read ↗

Detection of mutated KRAS, TP53, CDKN2A, and SMAD4 in tumor cell-free DNA of Brazilian pancreatic adenocarcinoma patients using next-generation sequencing.Semantic proximity Read ↗

Whole exome sequencing and RNA sequencing analyses of PDAC samplesSemantic proximity Read ↗

Pancreatic ductal adenocarcinomas from Mexican patients present a distinct genomic mutational pattern.Semantic proximity Read ↗

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.Semantic proximity Read ↗

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersSemantic proximity Read ↗

Detection of mutated KRAS, TP53, CDK2A, and SMAD4 in tumor cell-free DNA of Brazilian pancreatic adenocarcinoma patients using next-generation sequencingSemantic proximity Read ↗

Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinomaSemantic proximity Read ↗

From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.